Loading...
•
Mar 31, 2021
Vir Q1 2021 Earnings Report
Vir Biotechnology reported financial results for the first quarter of 2021 and provided a corporate update.
Key Takeaways
Vir Biotechnology reported total revenues of $2.0 million and a net loss of $168.9 million for the first quarter ended March 31, 2021. The company highlighted progress in its COVID-19 and hepatitis B programs, including the Phase 3 trial results of VIR-7831 and collaborations with Gilead and GSK.
VIR-7831 Phase 3 trial demonstrated an 85% reduction in hospitalization or death.
Emergency Use Authorization request submitted to the FDA for VIR-7831.
European Medicines Agency initiated a review of VIR-7831.
Expanded collaboration with GSK to include research and development of new therapies for influenza and other respiratory viruses.
Revenue by Segment
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...